cv 3988 has been researched along with leukotriene e4 in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (50.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Inagaki, N; Koda, A; Miura, T; Nagai, H; Ohira, K; Xu, QA | 1 |
| Northover, AM | 1 |
2 other study(ies) available for cv 3988 and leukotriene e4
| Article | Year |
|---|---|
Effect of CV-3988, a specific antagonist against platelet activating factor, on homologous passive cutaneous anaphylaxis in the mouse ear.
Topics: Alprostadil; Animals; Antibodies; Blood Vessels; Dinoprostone; Ear, External; Female; Histamine; Immunoglobulin E; Immunoglobulin G; Leukotriene E4; Mice; Mice, Inbred BALB C; Passive Cutaneous Anaphylaxis; Permeability; Phospholipid Ethers; Platelet Activating Factor; Serotonin; Skin; SRS-A | 1990 |
Effects of PAF and PAF antagonists on the shape of venous endothelial cells in vitro.
Topics: Animals; Calcimycin; Diterpenes; Electron Spin Resonance Spectroscopy; Endothelium, Vascular; Furans; Ginkgolides; Guinea Pigs; Lactones; Leukotriene E4; Lysophosphatidylcholines; Phospholipid Ethers; Platelet Activating Factor; SRS-A; Vena Cava, Inferior | 1989 |